Predictive Technology Group (OTC: PRED), through wholly owned subsidiaries, is engaged in the treatment of debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and proteins play in the onset and progression of disease. PRED’s subsidiaries use gene-based information in the development of new diagnostics that assess risk of illness and therapeutic products designed to prevent and treat diseases effectively. For more information, visit the company’s website at www.predictivetechnologygroup.com